

Haematologica  
HAEMATOL/2018/202200  
Version 3

Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients

John R. Jones, Niels Weinhold, Cody Ashby, Brian A. Walker, Christopher Wardell, Charlotte Pawlyn, Leo Rasche, Lorenzo Melchor, David A. Cairns, Walter M. Gregory, David Johnson, Dil B. Begum, Sidra Ellis, Amy L. Sherborne, Gordon Cook, Martin F. Kaiser, Mark T. Drayson, Roger G. Owen, Graham H. Jackson, Faith E. Davies, Mel Greaves, and Gareth J. Morgan

Disclosures: We are thankful to all the patients who have taken part in the Myeloma XI trial, from which samples used in this analysis were obtained. We thank the Data Monitoring and Ethics Committee (DMEC) and Trial Steering Group Committee (TSG) for their support and guidance throughout the trial. Myeloma XI was funded by Cancer Research UK and received an unrestricted educational grant from Celgene, Takeda and Merck. No potential conflicts of interest were disclosed.

Contributions: Conception and design JJ, GJM and MG; Development of methodology JJ, NW, CA, BW, LM and CW; Acquisition of data JJ, NW, CA, LM, PB and SE; Analysis and interpretation of data JJ, NW, GJM, MG, CA, CP and CW; Writing, review and/or revision of the manuscript All authors.